昆药集团半年报：营收净利双降，富国、广发旗下基金持仓大减

Core Viewpoint - Kunming Pharmaceutical Group reported a decline in revenue and net profit for the first half of the year, primarily due to delays in the implementation of national traditional Chinese medicine procurement, accelerated integration of retail pharmacies, and healthcare cost control policies affecting outpatient demand [1] Financial Performance - Revenue for the first half of the year was 3.351 billion yuan, a year-on-year decrease of 11.68% [1] - Net profit attributable to shareholders was 198 million yuan, down 26.88% year-on-year [1] Market Activity - During the reporting period, the Fuguo Tianhui Selected Growth Mixed Securities Investment Fund (LOF) and Fuguo Research Selected Flexible Allocation Mixed Securities Investment Fund collectively reduced their holdings by 13,585,200 shares [1] - The GF Healthcare Stock Type Securities Investment Fund reduced its holdings by 2,548,100 shares [1]